Novo Nordisk Acquires Global Rights To Zaltenibart From Omeros; Omeros Is Eligible To Receive $340M In Upfront And Near-Term Milestone Payments, Up To A Total Of $2.1B

Author: Benzinga Newsdesk | October 15, 2025 08:34am

• Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk's Rare Disease portfolio
• Omeros is eligible to receive 340 million US dollars in upfront and near-term milestone payments, up to a total of 2.1 billion dollars including potential development and commercial milestones, plus tiered royalties on net sales

Bagsværd, Denmark and Seattle, US, 15 October 2025 – Novo Nordisk and Omeros Corporation (NASDAQ:OMER) today announced that they have entered into a definitive asset purchase and license agreement for the candidate drug zaltenibart (formerly OMS906) in clinical development for rare blood and kidney disorders.

Under the terms of the agreement, Novo Nordisk will be granted exclusive global rights to develop and commercialise zaltenibart in all indications. Omeros is eligible to receive 340 million US dollars in upfront and near-term milestone payments, up to a total of 2.1 billion dollars including potential development and commercial milestones, plus tiered royalties on net sales.

Zaltenibart is an antibody designed to inhibit MASP-3, a protein that acts as a key activator of the complement system's alternative pathway. Dysregulation of the complement system, a crucial part of the immune system, has been shown to be involved in the pathophysiology of a number of rare diseases.

Posted In: NVO OMER